Which has higher earnings and valuation, OGN or ANNX?

Organon & Co. has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organon & Co. $6.22B 0.57 $187M $0.93 14.40 Annexon N/A N/A -$206.69M -$1.22 N/A

Is OGN or ANNX more profitable?

Organon & Co. has a net margin of 3.99% compared to Annexon's net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Organon & Co. 3.99% 99.95% 6.22% Annexon N/A -101.19% -75.99%

Which has higher valuation & earnings, ORKA or ANNX?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oruka Therapeutics N/A N/A -$105.43M -$1.94 N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is ORKA or ANNX more profitable?

Oruka Therapeutics' return on equity of -26.16% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -26.16% -25.00% Annexon N/A -101.19% -75.99%

Does the media refer more to ORKA or ANNX?

In the previous week, Oruka Therapeutics and Oruka Therapeutics both had 4 articles in the media. Annexon's average media sentiment score of 1.29 beat Oruka Therapeutics' score of 1.11 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BEAM or ANNX more profitable?

Annexon has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Beam Therapeutics -39.66% -29.00% -22.61% Annexon N/A -101.19% -75.99%

Does the media prefer BEAM or ANNX?

In the previous week, Beam Therapeutics and Beam Therapeutics both had 4 articles in the media. Annexon's average media sentiment score of 1.29 beat Beam Therapeutics' score of 0.81 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or DNLI more profitable?

Denali Therapeutics' return on equity of -52.20% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Denali Therapeutics N/A -52.20% -43.86%

Does the media favor ANNX or DNLI?

In the previous week, Annexon had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Annexon and 2 mentions for Denali Therapeutics. Annexon's average media sentiment score of 1.29 beat Denali Therapeutics' score of 1.26 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ANNX or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Annexon. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.22 N/A Telix Pharmaceuticals $803.79M 3.70 -$7.12M N/A N/A

Is ANNX or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Telix Pharmaceuticals N/A N/A N/A

Does the media prefer ANNX or TLX?

In the previous week, Annexon and Annexon both had 4 articles in the media. Annexon's average media sentiment score of 1.29 beat Telix Pharmaceuticals' score of 0.38 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Annexon (ANNX) Competitors

$5.39 +0.13 (+2.47%)

Closing price 04:00 PM Eastern

Extended Trading

$5.33 -0.06 (-1.11%)

As of 07:44 PM Eastern

Compare

ANNX vs. OGN, ORKA, BEAM, DNLI, and TLX

Should you buy Annexon stock or one of its competitors? MarketBeat compares Annexon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Annexon include Organon & Co. (OGN), Oruka Therapeutics (ORKA), Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry.

How does Annexon compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Organon & Co. has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.40
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Organon & Co. currently has a consensus price target of $11.40, indicating a potential downside of 14.89%. Annexon has a consensus price target of $16.00, indicating a potential upside of 196.85%. Given Annexon's stronger consensus rating and higher possible upside, analysts plainly believe Annexon is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Annexon had 4 more articles in the media than Organon & Co.. MarketBeat recorded 4 mentions for Annexon and 0 mentions for Organon & Co.. Annexon's average media sentiment score of 1.29 beat Organon & Co.'s score of 0.50 indicating that Annexon is being referred to more favorably in the news media.

Company	Overall Sentiment
Organon & Co.	Positive
Annexon	Positive

Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Annexon has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Organon & Co. has a net margin of 3.99% compared to Annexon's net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Annexon	N/A	-101.19%	-75.99%

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 10.3% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Organon & Co. beats Annexon on 9 of the 15 factors compared between the two stocks.

How does Annexon compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Oruka Therapeutics and Oruka Therapeutics both had 4 articles in the media. Annexon's average media sentiment score of 1.29 beat Oruka Therapeutics' score of 1.11 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics currently has a consensus price target of $131.30, suggesting a potential upside of 129.55%. Annexon has a consensus price target of $16.00, suggesting a potential upside of 196.85%. Given Annexon's higher probable upside, analysts clearly believe Annexon is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Oruka Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market. Comparatively, Annexon has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oruka Therapeutics' return on equity of -26.16% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Annexon	N/A	-101.19%	-75.99%

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Summary

Oruka Therapeutics beats Annexon on 7 of the 12 factors compared between the two stocks.

How does Annexon compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Beam Therapeutics and Beam Therapeutics both had 4 articles in the media. Annexon's average media sentiment score of 1.29 beat Beam Therapeutics' score of 0.81 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annexon has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Annexon	N/A	-101.19%	-75.99%

99.7% of Beam Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 10.3% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than Annexon. Beam Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.76	-$79.99M	-$0.68	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Beam Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, Annexon has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Beam Therapeutics currently has a consensus price target of $46.83, indicating a potential upside of 58.49%. Annexon has a consensus price target of $16.00, indicating a potential upside of 196.85%. Given Annexon's higher probable upside, analysts clearly believe Annexon is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Beam Therapeutics beats Annexon on 10 of the 15 factors compared between the two stocks.

How does Annexon compare to Denali Therapeutics?

Annexon (NASDAQ:ANNX) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Annexon currently has a consensus target price of $16.00, suggesting a potential upside of 196.85%. Denali Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 74.21%. Given Annexon's higher probable upside, equities analysts plainly believe Annexon is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

In the previous week, Annexon had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Annexon and 2 mentions for Denali Therapeutics. Annexon's average media sentiment score of 1.29 beat Denali Therapeutics' score of 1.26 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics' return on equity of -52.20% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Denali Therapeutics	N/A	-52.20%	-43.86%

Annexon has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Annexon has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Denali Therapeutics	$330.53M	9.44	-$512.54M	-$2.88	N/A

92.9% of Denali Therapeutics shares are owned by institutional investors. 10.3% of Annexon shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Denali Therapeutics beats Annexon on 8 of the 15 factors compared between the two stocks.

How does Annexon compare to Telix Pharmaceuticals?

Annexon (NASDAQ:ANNX) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Annexon and Annexon both had 4 articles in the media. Annexon's average media sentiment score of 1.29 beat Telix Pharmaceuticals' score of 0.38 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Annexon presently has a consensus price target of $16.00, suggesting a potential upside of 196.85%. Telix Pharmaceuticals has a consensus price target of $21.13, suggesting a potential upside of 140.88%. Given Annexon's higher possible upside, equities research analysts clearly believe Annexon is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Annexon has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market.

Telix Pharmaceuticals' return on equity of 0.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Telix Pharmaceuticals	N/A	N/A	N/A

Telix Pharmaceuticals has higher revenue and earnings than Annexon.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Telix Pharmaceuticals	$803.79M	3.70	-$7.12M	N/A	N/A

Summary

Telix Pharmaceuticals beats Annexon on 7 of the 10 factors compared between the two stocks.

Get Annexon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANNX vs. The Competition

Export

Metric	Annexon	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$861.81M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-4.42	17.78	22.39	24.18
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	3.80	6.63	9.84	6.72
Net Income	-$206.69M	$24.20M	$3.57B	$337.19M
7 Day Performance	N/A	-3.24%	-1.16%	0.48%
1 Month Performance	-6.26%	0.53%	3.85%	5.07%
1 Year Performance	134.35%	47.24%	27.40%	34.25%

Annexon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANNX Annexon	3.1403 of 5 stars	$5.39 +2.5%	$16.00 +196.8%	+148.1%	$861.81M	N/A	N/A	60	Positive News
OGN Organon & Co.	2.3956 of 5 stars	$13.36 -0.2%	$11.40 -14.6%	+45.2%	$3.51B	$6.22B	14.36	10,000
ORKA Oruka Therapeutics	3.6905 of 5 stars	$57.98 0.0%	$120.80 +108.3%	+369.2%	$3.50B	N/A	N/A	N/A	Positive News Analyst Forecast
BEAM Beam Therapeutics	2.1129 of 5 stars	$32.80 +2.9%	$46.83 +42.8%	+78.9%	$3.37B	$139.74M	N/A	510
DNLI Denali Therapeutics	3.7179 of 5 stars	$20.95 +3.7%	$34.25 +63.5%	+38.6%	$3.32B	$330.53M	N/A	430	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANNX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annexon (ANNX) Competitors

ANNX vs. OGN, ORKA, BEAM, DNLI, and TLX

How does Annexon compare to Organon & Co.?

Summary

How does Annexon compare to Oruka Therapeutics?

Summary

How does Annexon compare to Beam Therapeutics?

Summary

How does Annexon compare to Denali Therapeutics?

Summary

How does Annexon compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annexon (ANNX) Competitors

ANNX vs. OGN, ORKA, BEAM, DNLI, and TLX

How does Annexon compare to Organon & Co.?

Which has higher earnings and valuation, OGN or ANNX?

Do analysts prefer OGN or ANNX?

Does the media prefer OGN or ANNX?

Which has more volatility and risk, OGN or ANNX?

Is OGN or ANNX more profitable?

Do insiders & institutionals believe in OGN or ANNX?

Summary

How does Annexon compare to Oruka Therapeutics?

Does the media refer more to ORKA or ANNX?

Do analysts prefer ORKA or ANNX?

Which has more volatility & risk, ORKA or ANNX?

Do institutionals & insiders have more ownership in ORKA or ANNX?

Is ORKA or ANNX more profitable?

Which has higher valuation & earnings, ORKA or ANNX?

Summary

How does Annexon compare to Beam Therapeutics?

Does the media prefer BEAM or ANNX?

Is BEAM or ANNX more profitable?

Do institutionals & insiders believe in BEAM or ANNX?

Which has stronger earnings and valuation, BEAM or ANNX?

Which has more risk & volatility, BEAM or ANNX?

Do analysts recommend BEAM or ANNX?

Summary

How does Annexon compare to Denali Therapeutics?

Do analysts recommend ANNX or DNLI?

Does the media favor ANNX or DNLI?

Is ANNX or DNLI more profitable?

Which has more volatility and risk, ANNX or DNLI?

Which has higher valuation and earnings, ANNX or DNLI?

Do institutionals & insiders have more ownership in ANNX or DNLI?

Summary

How does Annexon compare to Telix Pharmaceuticals?

Does the media prefer ANNX or TLX?

Do analysts prefer ANNX or TLX?

Which has more volatility and risk, ANNX or TLX?

Is ANNX or TLX more profitable?

Which has stronger earnings & valuation, ANNX or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools